Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.58 |
| ▸ | EGFR | P00533 | 7/20 | 0.58 |
| ▸ | ABL1 | P00519 | 5/20 | 0.57 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27082276 | 0.93 | ABL1 (0.64) | BRAFEGFRABL1KITRET | |
| SCHEMBL27083160 | 0.91 | BRAF (0.68) | BRAFEGFRABL1KITBCR | |
| SCHEMBL27082370 | 0.90 | KIT (0.63) | BRAFEGFRABL1KITBCR | |
| SCHEMBL27083161 | 0.89 | BRAF (0.68) | BRAFEGFRABL1KITBCR | |
| SCHEMBL27082299 | 0.87 | BRAF (0.59) | BRAFEGFRABL1KITBCR | |
| SCHEMBL27083097 | 0.86 | EGFR (0.68) | BRAFEGFRABL1BCR | |
| SCHEMBL27081498 | 0.86 | ABL1 (0.58) | BRAFEGFRABL1KITBCR | |
| SCHEMBL29967913 | 0.86 | ABL1 (0.58) | BRAFEGFRABL1KITBCR | |
| SCHEMBL29967530 | 0.85 | ABL1 (0.54) | BRAFEGFRABL1KITBCR | |
| SCHEMBL27081695 | 0.85 | ABL1 (0.54) | BRAFEGFRABL1KITBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313292-B1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARM SPA (IT) | 2026-02-18 | — | — | EP | claimed |
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | claimed |
| EP-4313292-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | claimed |
| CN-117120434-A | Indoline derivatives as DDR1 and DDR2 inhibitors | 奇斯药制品公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4313292-B1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARM SPA (IT) | 2026-02-18 | — | — | EP | disclosed |
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | DDR1, DDR2, DDRGK1 | BRAF 2934/4885EGFR 482/4885ABL1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.